Wednesday - February 18, 2026
GSK's Arexvy Associated With Reductions in Certain RSV-Related Risks Including Heart Attack, Stroke and Severe Flare-Ups of COPD and Asthma, Real World Study Shows
February 18, 2026
LONDON, England, Feb. 18 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Feb. 17, 2026:

* * *

GSK's Arexvy associated with reductions in certain RSV-related risks including heart attack, stroke and severe flare-ups of COPD and asthma, real world study shows

- Reduction observed in RSV-related hospitalisations in adults aged 60 years/1

- An observed reduction in major adverse cardiovascul . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products